We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Coronavirus-Detecting Breathing Device Could Potentially Give a Diagnosis in Less than One Minute

By LabMedica International staff writers
Posted on 20 Apr 2020
Print article
Image: Coronavirus-detecting breathing device could potentially give a diagnosis in less than one minute (Photo courtesy of Northumbria University)
Image: Coronavirus-detecting breathing device could potentially give a diagnosis in less than one minute (Photo courtesy of Northumbria University)
Researchers from two different parts of the world have developed a new method using a breathing device that could revolutionize the way diseases, such as the newly emerged strain of coronavirus, COVID-19, are diagnosed.

Two Israeli companies, Next-Gen and Scentech Medical, have jointly developed a coronavirus-detecting breathing device based on the breathalyzer machine used by the police for detecting alcohol levels in a person’s blood stream. When the patient breathes into the device, it can distinguish between thousands of gas compounds in the breath and then isolate the ones associated with the coronavirus, enabling a quick and simple diagnosis in less than a minute. In addition to significantly reducing the amount of time to achieve results due to its ability to deliver a diagnosis in minutes, the coronavirus-detecting breathing device can quickly identify and diagnose asymptomatic patients, as well as patients in the early stages of the disease, thus enabling a more efficient quarantine approach. The device is also capable of identifying the virus's genetic 'fingerprint.' – allowing for the detection of the genetic fingerprint of the next potential pandemic-causing virus even before it can do major damage.

Similarly, academics at Northumbria University (Newcastle, England) have developed a new device which enables diagnosis of disease through breath collection. Their new device allows sampling of the lung in a non-invasive way - by patients breathing into it - to retrieve biomarkers, such as DNA, RNA, proteins, and lipids found in the breath that have diagnostic potential for diseases of the lung and beyond. To date, systems that diagnose from breath sampling have not proven to be reliable enough due to contamination, sample loss and variability issues in breath analysis. However, the new device resolves these issues so that the data collected through this pioneering invention closely resembles results from lung samples taken surgically. It is hoped that in the future the technology could be used in the diagnosis of lung diseases as well as other health issues such as diabetes, cancers, liver problems, brain and ageing diseases.

“In the case of coronavirus, temperature monitoring in airports is not sufficient,” said Dr Sterghios Moschos, Associate Professor at Northumbria University, who led the study whilst at Westminster University. “The World Health Organization currently recommends testing nasal swabs, oral swabs and swabs from inside the lungs to avoid missing the infection. That’s why it’s vital that we develop non-invasive, quick and cost-effective tests for diagnosis and screening.”

Related Links:
Northumbria University

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.